News

The findings of a new preclinical study in pulmonary sarcoidosis are lending support to the therapeutic potential of efzofitimod, a treatment candidate from Atyr Pharma now being tested in a Phase 3 clinical trial. The researchers found that a protein called HARS-WHEP — whose activity is mimicked by…

Nearly 1 in 10 people with pulmonary sarcoidosis also have heart involvement, or cardiac sarcoidosis, at the time of their initial diagnosis with the rare inflammatory disease occurring in the lungs, according to a study in Japan. Further, another 3.8% of patients subsequently develop cardiac sarcoidosis, the data…

The Foundation for Sarcoidosis Research (FSR) is partnering with Walgreens and Cedars-Sinai to provide free N95 face masks at two locations in Los Angeles, with the goal of helping members of the community protect their lungs following January’s wildfires. Exposure to fine particulate matter from soot and ash in…

April is Sarcoidosis Awareness Month, and this year’s theme, as chosen by the Foundation for Sarcoidosis Research (FSR), is “Facing Sarcoidosis Together” — which seeks to recognize the unique ways in which community, support, and advocacy can help patients navigate their disease. “Living with sarcoidosis presents significant challenges,…

Enrollment is complete in the dose-finding phase of a Phase 1b/2b clinical trial evaluating Xentria’s investigational therapy XTMAB-16 in adults with pulmonary sarcoidosis, and screening for the next phase is expected to start next fall. The Phase 1b/2 study (NCT05890729) enrolled 39 pulmonary sarcoidosis patients in four…

Atyr Pharma and the U.S. Food and Drug Administration (FDA) have aligned on the specific main outcome analysis of the ongoing Phase 3 clinical trial that’s testing the company’s investigational therapy efzofitimod in people with pulmonary sarcoidosis. Based on FDA feedback during a recent type C meeting,…

The National Organization for Rare Disorders (NORD) is seeking participants for its survey-based study Living Rare, which aims to better understand the real-world lived experiences of people in the U.S. with rare diseases. Living Rare, the first large-scale study of its kind in the U.S., seeks to capture the…

The U.S. Food and Drug Administration (FDA) has approved a prefilled syringe version of purified Cortrophin Gel (repository corticotropin injection) as an add-on treatment for people with symptoms of sarcoidosis. Sold by Ani Pharmaceuticals, the original vial format of Corticotrophin Gel received FDA clearance in 2021 to treat…

Autoimmune responses against healthy proteins in the retina, which is the back of the eye, could play a role in driving a type of eye inflammation called uveitis in people with ocular sarcoidosis, per a new study. According to the researchers, self-reactive antibodies against the retina were found more…

People with sarcoidosis who live in the U.S. are most concerned about their disease worsening, developing in more organs, or not lessening, according to the results of an online survey developed by both patients and doctors that was used to query more than 1,000 individuals. Per the findings, patients…